KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 3.54%.

  • Pacira BioSciences' EBITDA Margin rose 863100.0% to 3.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.8%, marking a year-over-year increase of 151400.0%. This contributed to the annual value of 10.47% for FY2024, which is 234600.0% down from last year.
  • Pacira BioSciences' EBITDA Margin amounted to 3.54% in Q3 2025, which was up 863100.0% from 4.69% recorded in Q2 2025.
  • Pacira BioSciences' 5-year EBITDA Margin high stood at 25.7% for Q2 2021, and its period low was 82.77% during Q3 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 11.01% (2022), whereas its average is 6.32%.
  • In the last 5 years, Pacira BioSciences' EBITDA Margin plummeted by -935800bps in 2024 and then skyrocketed by 863100bps in 2025.
  • Quarter analysis of 5 years shows Pacira BioSciences' EBITDA Margin stood at 2.65% in 2021, then plummeted by -317bps to 5.75% in 2022, then skyrocketed by 418bps to 18.3% in 2023, then dropped by -28bps to 13.19% in 2024, then tumbled by -73bps to 3.54% in 2025.
  • Its EBITDA Margin was 3.54% in Q3 2025, compared to 4.69% in Q2 2025 and 1.18% in Q1 2025.